Lipid-lowering therapy: Strategies for improving compliance

Current Medical Research and Opinion

Volumn 20, Issue 2, 2004, Pages 165-173

  Riesen, Walter F ^a   Darioli, Roger ^b   Noll, Georg ^c  

^a Kantonsspital   (Switzerland)

^b POLICLINIQUE MÉDICALE UNIVERSITAIRE   (Switzerland)

^c Stadtspital Triemli Departement fur Innere Medizin Abteilung fur Gastroenterologie   (Switzerland)

Author keywords

Compliance; Coronary heart disease; Low density lipoprotein cholesterol; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; FLUINDOSTATIN; GEMFIBROZIL; LIPID; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID BLOOD LEVEL; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; RISK REDUCTION; SIDE EFFECT; TREATMENT FAILURE;

CORONARY DISEASE; EUROPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PATIENT COMPLIANCE; PATIENT EDUCATION;

EID: 1042291223     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002810     Document Type: Review

References (84)

1. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434-503
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
3. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:354-72
4. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67
5. Hunninghake D, Bakker-Arkema RG, Wigand JP, et al. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract 1998;47:349-56
6. Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998;32:665-72
7. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001;111:185-91
8. Olsson AG, Istad H, Luurila O, et al. Rosuvastatin Investigators Group. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144:1044-51
9. Brown WV, Bays HE, Hassman DR, et al. Rosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036-43
10. Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003;91:11-17C
11. EUROASPIRE Study Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease, principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18:1569-82
12. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357:995-1001
13. Muls E, De Backer G, De Bacquer D, Brohet M, Heller F. LIPI-WATCH, a Belgian/Luxembourg survey on achievement of European Atherosclerosis Society lipid goals. Clin Drug Invest 2000;19:219-29
14. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000;321:1322-5
15. Reid FDA, Cook DG, Whincup PH. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002;88:15-19
16. Whincup PH, Emberson JR, Lennon L, Walker M, Papacosta O, Thomson A. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart 2002;88:25-9
17. Ito MK, Delucca GM, Aldridge MA. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events. J Cardiovasc Pharmacol Ther 2001;6:129-35
18. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2002;18:499-502
19. Durrington P. The human and economic costs of undertreatment with statins. Int J Clin Pract 2002;56:357-68
20. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996;100:605-10
21. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-31
22. Frolkis JP, Pearce GL, Nambi V, Minor S, Sprecher DL. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002;113:625-9
23. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
24. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
25. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-9
26. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22
27. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
28. West of Scotland Coronary Prevention Study Group. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997;18:1718-24
29. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002;88:229-33
30. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208-11
31. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7
32. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherance to treatment in chronic physical illness. J Psychosom Res 1999;47:555-67
33. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J. Persistance of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-62
34. Larsen J, Andersen M, Kragstrup J, Gram LF. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol 2002;53:375-8
35. LaRosa JH, LaRosa JC. Enhancing drug compliance in lipid-lowering treatment. Arch Fam Med 2000;9:1169-75
36. Hée P. Compliance to estrogen treatment one to three years after hysterectomy and bilateral salpingooophorectomy. The cohort's lifestyle, knowledge of ERT, benefits etc. Acta Obstet Gynecol Scand 1999;78:534-9
37. Shepherd J. From best evidence to best practice - what are the obstacles? Atherosclerosis 1999;147:S45-S51
38. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61
39. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990;150:841-5
40. Baird MG, Bentley-Taylor MM, Carruthers SG, et al. A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc) in hypertension. Betaloc Compliance Canadian Cooperative Study Group. Clin Invest Med 1984;7:95-102
41. Brown BG, Bardsley J, Poulin D, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 1997;80:111-15
42. Sung JC, Nichol MB, Venturini F, et al. Factors affecting patient compliance with antihyperlipidemic medications in HMO population. Am J Manag Care 1998;4:1421-30
43. Kim YS, Sunwoo S, Lee HR, et al. Korea Post-Marketing Surveillance Research Group. Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients. Pharmacoepidemiol Drug Saf 2002;11:593-600
44. Bruckert E, Simonetta C, Giral P. Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study Team. J Clin Epidemiol 1999;52:589-94
45. Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications for primary care. Am J Manag Care 1999;5:437-44
46. Tsuyuki RT, Bungard TJ. Poor adherence with hypolipidemic drugs: a lost opportunity. Pharmacotherapy 2001;21:576-82
47. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-70
48. Heart Protection Study collaborative group. The MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;56:53-6
49. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES) study. Am J Cardiol 1998;81:582-7
50. Jones PH, Davidson MH, Stein EA, et al. for the STELLAR Study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-60
51. Schuster H. Managing the high-risk patient: therapeutic approaches in 2002. Atheroscler Suppl 2003;4:15-20
52. Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003;92(Suppl 2):23-9
53. Clark LT. Treating dyslipidemia with statins: the risk-benefit profile. Am Heart J 2003;145:387-96
54. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism - monograph for physicians. Arch Intern Med 2000;160:2273-80
55. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 2003;4:9-14
56. Marquez Contreras E, Casado Martinez JJ, et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Aten Primaria 1998;22:79-84
57. Inui TS, Yourtee EL, Williamson JW. Improved outcomes in hypertension after physician tutorials. A controlled trial. Ann Intern Med 1976;84:646-51
58. Morisky DE, Levine DM, Green LW, Shapiro S, Russell RP, Smith CR. Five-year blood pressure control and mortality following health education for hypertensive patients. Am J Public Health 1983;73:153-62
59. Winslow E, Bohannon N, Brunton SA, Mayhew HE. Lifestyle modification: weight control, exercise, and smoking cessation. Am J Med 1996;101:4A25S-A31S
60. Becker MH, Maiman LA. Strategies for enhancing patient compliance. J Community Health 1980;6:113-35
61. Mahler HI, Kulik JA, Tarazi RY. Effects of a videotape information intervention at discharge on diet and exercise compliance after coronary bypass surgery. J Cardiopulm Rehabil 1999;19:170-7
62. Lindsay G, Hinnie J, Gaw A. Setting up a helpline on heart disease. Nurs Stand 1995;10:27-30
63. Schwed A, Fallab CL, Burnier M, Waeber B, Kappenberger L, Burnand B, Darioli R. Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. J Clin Pharmacol 1999;39:402-9
64. Kruse W, Weber E. Dynamics of drug regimen compliance - its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol 1990;38:561-5
65. Kirkman MS, Weinberger M, Landsman PB, Samsa GP, Shortliffe EA, Simel DL, Feussner JR. A telephone-delivered intervention for patients with NIDDM. Effect on coronary risk factors. Diabetes Care 1994;17:840-6
66. Friedman RH, Kazis LE, Jette A, Smith MB, Stollerman J, Torgerson J, Carey K. A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherance and blood pressure control. Am J Hypertens 1996;9:285-92
67. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy 2000;20:410-16
68. Robinson JG, Conroy C, Wickerneyer WJ. A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol < or = 100 mg/dl. Am J Cardiol 2000;85:305-8
69. Schectman G, Hiatt J, Hartz A. Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Ann Pharmacother 1994;28:29-35
70. Schectman G, Wolff N, Byrd JC, Hiatt JG, Hartz A. Physician extenders for cost-effective management of hypercholesterolemia. J Gen Intern Med 1996;11:277-86
71. Eraker SA, Kirscht JP, Becker MH, Arbor A. Understanding and improving patient compliance. Ann Intern Med 1984;100:258-68
72. Aubin M, Godin G, Vezina L, Maziade J, Desharnais R. Hypercholesterolemia screening. Does knowledge of blood cholesterol level affect dietary fat intake? Can Fam Physician 1998;44:1289-97
73. Guthrie RM. The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clin Ther 2001;23:970-80
74. Willich SN, Müller-Nordhorn J, Upmeier H, et al. Economic evaluation of a compliance program in patients with statin therapy - design and pilot phase of the ORBITAL study. Circulation 2002;106:E81
75. Ammerman AS, DeVellis RF, Carey TS, et al. Physician-based diet counseling for cholesterol reduction: current practices, determinants, and strategies for improvement. Prev Med 1993;22:96-109
76. Taylor CB, Houston-Miller N, Killen JD, DeBusk RF. Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention. Ann Intern Med 1990;113:118-23
77. Lenaghan NA. The nurse's role in smoking cessation. Medsurg Nurs 2000;9:298-301
78. Lancaster T, Stead L, Shepperd S. Helping parents to stop smoking: which interventions are effective? Paediatr Respir Rev 2001;2:222-6
79. Reeve K, Calabro K, Adams-McNeill J. Tobacco cessation intervention in a nurse practitioner managed clinic. J Am Acad Nurse Pract 2000;12:163-9
80. Smith PM, Reilly KR, Houston Miller N, DeBusk RF, Taylor CB. Application of a nurse-managed inpatient smoking cessation program. Nicotine Tob Res 2002;4:211-22
81. DeBusk RF, Miller NH, Superko HR, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 1994;120:721-9
82. Konzem SL, Gray DR, Kashyap ML. Effect of pharmaceutical care on optimum colestipol treatment in elderly hypercholesterolemic veterans. Pharmacotherapy 1997; 17:576-83
83. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT hyperlipidemia. J Am Pharm Assoc 2000;40:157-65
84. Yates S, Annis L, Pippins J, Walden S. Does a lipid clinic increase compliance with National Cholesterol Education Program Treatment Guidelines? Report of a case-matched controlled study. South Med J 2001;94:907-9